How long can vaccine-derived spike protein be detected after mRNA vaccination?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Multiple peer‑reviewed and non‑peer sources report vaccine‑derived SARS‑CoV‑2 spike protein can be detected for periods ranging from days to many months after mRNA vaccination, with documented findings at roughly 3 weeks, 2 months, 3–4 months and in some reports out to 245–709 days; results vary by tissue studied, detection method and patient group [1] [2] [3] [4] [5]. Interpretations diverge: some authors view long detection as expected biology of antigen presentation, while others argue it could explain prolonged symptoms—both positions rest on limited and heterogeneous evidence [1] [3] [4].
1. What the data actually show: snapshots across tissues and time
Immunohistochemistry of a persistent skin lesion found vaccine‑encoded spike protein in keratinocytes and endothelial cells more than three months after BNT162b2 vaccination (case report) [2]; germinal‑centre lymphoid tissue studies have detected vaccine mRNA and spike protein roughly two months post‑vaccination [1]; circulation‑focused assays have measured spike or S1 subunit in plasma or on exosomes in the weeks to months after injections (measurable until ~three weeks in one symptomatic cohort, and exosome‑associated spike reported at least four months post‑dose in commentary on Ogata et al.) [1] [3]. Acute post‑vaccine myocarditis cases showed free full‑length spike protein in plasma at the time of illness, while asymptomatic controls often had no detectable free spike using the same methods [5] [6].
2. Longer persistence claims — what’s robust and what isn’t
A now‑circulating claim of spike detected up to 245 days in CD16+ monocytes comes from a recent 2025 report of symptomatic, vaccine‑only individuals and is presented by advocacy outlets as evidence of long‑term persistence; that same outlet cites an unpublished Yale claim of detection at 709 days [4]. These longer‑duration assertions appear in non‑peer outlets or prepublication claims and have not yet been broadly replicated in independent, large, peer‑reviewed studies; consequently their generalizability is uncertain [4].
3. Why results differ: methods, sample type and clinical context
Different assays (mass spectrometry, immunohistochemistry, sensitive plasma ELISAs, exosome isolation) target different forms of spike (full‑length vs S1 fragment) and different compartments (blood plasma, immune cells, lymphoid tissue, skin), producing disparate detection windows; for example, exosome‑associated spike may be detectable longer than free circulating protein, and tissue immunostaining can find localized antigen where plasma assays are negative [3] [1] [2].
4. Interpretation and limits: detection ≠ ongoing dangerous synthesis
Detection of spike protein does not alone demonstrate continued active mRNA translation, systemic toxicity, or causation of symptoms; authors note uncertainty whether persistence reflects lingering mRNA, protein on exosomes or immune‑cell uptake, and many studies are small or case‑based so cannot establish population‑level risk [1] [3]. Peer‑reviewed work documents temporary circulation of spike in some clinical scenarios (e.g., myocarditis) and localized persistence in isolated cases, but does not prove a universal, long‑lived production state across all vaccinees [5] [6] [2].
5. Competing narratives and potential agendas in the literature
Groups such as Doctors for COVID Ethics and certain advocacy outlets highlight longer‑persistence findings and emphasize potential harms, sometimes citing small or non‑peer‑reviewed studies [3] [4]; mainstream biomedical publications focus on mechanism, immune response kinetics and emphasize the need for larger, controlled investigations [1] [5]. Readers should note advocacy organizations may select data to support clinical or policy arguments, while journal articles frequently flag limitations and the need for replication [3] [1].
6. Bottom line for the question asked
Available evidence demonstrates vaccine‑derived spike protein can be detected from days up to several months after mRNA vaccination in different compartments (plasma, exosomes, lymphoid tissue, skin)—conservative, peer‑reviewed findings document detection at roughly three weeks to two months in some contexts and localized detection at >3 months in case reports, while newer, less‑replicated reports claim persistence out to 245–709 days but require independent validation before being accepted as generalizable [1] [2] [3] [4] [5].